Business Wire

DIGITAL-ELEMENT

30.6.2020 09:02:11 CEST | Business Wire | Press release

Share
Seeding Alliance Sees Significant Boost in Engagement Following Partnership With Digital Element

Seeding Alliance , a leading specialist in native advertising, has seen significantly improved performance following its partnership with Digital Element , the global geolocation and audience insights provider, with click-through rates boosted by as much as 20%. Having chosen Digital Element’s NetAcuity PulseTM technology, the Cologne-based native advertising experts now offer enhanced geo-based ad serving for their clients as well as in-depth traffic analysis for fraud identification.

Based in Germany, Seeding Alliance is one of the leaders in native advertising - a core tactic to engage consumers. By placing ads that authentically match the feel and function of the media in which they reside, Seeding Alliance allows the publishing of content that effectively targets relevant audiences without disrupting the natural editorial format of the publication.

Seeding Alliance selected Digital Element’s NetAcuity Pulse IP intelligence solution in May 2019 to improve their geolocation services and gain access to global IP datasets, enabling segmentation of relevant audiences based on various information layers – such as connection type, mobile carrier and internet service provider – without the user becoming personally identifiable. This has clearly helped to ensure the success of Seeding Alliance’s clients’ advertising campaigns, as consumers can be targeted with appropriate and relevant geo-location based ads to efficiently utilise advertising budgets and minimise fraud.

“Our previous solution choices were simply too inaccurate and incomplete, which led us to the decision to move data providers and choose the market leader, Digital Element, to achieve the best possible results for our clients,” commented Adrian Meyer, VP Technology at Seeding Alliance. “Shortly after the integration of the Digital Element data we realised that we were successfully blocking more fraud attempts and that the advertising campaigns were performing better. We have always been keen to provide sustainable increase in brand awareness, across extensive formats, without compromising consumer convenience and this partnership with Digital Element means we can now effectively target more tightly defined audiences, through the use of location specific content and IP intelligence.”

Digital Element’s NetAcuity Pulse™ uses a network of IP location information derived from mobile devices, billions of on-device-location transactions, and internet routing infrastructure. This very precise – yet privacy-sensitive – global online targeting method is based on where a user is located and connected at a specific point in time, regardless of device. Information can include whether or not the connection is being made through a wifi network, the user’s point-in-time geographic location, and whether a home or business hotspot is in use. The benefits of using intelligent and precise targeting at scale include increased revenues, better return on investment, stronger brand loyalty, and improved consumer engagement.

“Seeding Alliance required a high level of accurate and intelligent support and we are delighted they chose our NetAcuity Pulse technology to assist them in tailoring their native advertising campaigns to target more specific audiences, and add to their armory for fighting ad fraud,” said Kate Owen, Digital Element’s Vice-President, Northern Europe. “We are proud of the accuracy of our data and one year on, it’s clear we have provided Seeding Alliance with valuable insights for them to continue to build on their success in this competitive advertising world.”

Seeding Alliance joins Digital Element’s portfolio of high-profile clients, which includes: Adobe, Facebook, Pinterest, LinkedIn, Taboola, Codewise, Amobee, Twitter, MediaMath, Adform, BBC, Discovery Networks, Hubspot, Vibrant Media, Webtrends, Crimtan, Weborama, Ogilvy and many others.

About Digital Element
Since 1999, Digital Element has been providing global geolocation and audience insights that bring anytime, anywhere relevance and context to online initiatives—from desktops to mobile devices. The company’s patented technology has been certified and accredited to deliver real-time access to accurate and reliable location intelligence without invading Internet users’ privacy. For over two decades, many of the world’s largest websites, brands, security companies, ad networks, social media platforms and mobile publishers have trusted Digital Element’s technology to target advertising, localize content, enhance analytics, and manage content rights as well as detect and prevent fraud.

Visit http://www.digitalelement.com for more information on how to bring the power of location to the online world. Follow us on LinkedIn and Twitter @DigitalElement then like us on Facebook .

Headquartered in Atlanta and London, Digital Element is a division of Digital Envoy Inc .

About Seeding Alliance
The Seeding Alliance GmbH is one of the leading marketers and developers of native advertising formats and the largest independent native advertising marketer in Germany. With a specially developed ad server for native forms of advertising, the Seeding Alliance is an innovative contact point for publishers and advertisers. Based in Cologne, Seeding Alliance was founded in 2011 by Coskun Tuna and Cevahir Ejder and has been part of the Ströer Group since March 2017.

Visit www.seeding-alliance.de for more information.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye